Literature DB >> 18443239

Regulator of G-protein signaling subtype 4 mediates antihypertrophic effect of locally secreted natriuretic peptides in the heart.

Takeshi Tokudome1, Ichiro Kishimoto, Takeshi Horio, Yuji Arai, Daryl O Schwenke, Jun Hino, Ichiro Okano, Yuhei Kawano, Masakazu Kohno, Mikiya Miyazato, Kazuwa Nakao, Kenji Kangawa.   

Abstract

BACKGROUND: Mice lacking guanylyl cyclase-A (GC-A), a natriuretic peptide receptor, have pressure-independent cardiac hypertrophy. However, the mechanism underlying GC-A-mediated inhibition of cardiac hypertrophy remains to be elucidated. In the present report, we examined the role of regulator of G-protein signaling subtype 4 (RGS4), a GTPase activating protein for G(q) and G(i), in the antihypertrophic effects of GC-A. METHODS AND
RESULTS: In cultured cardiac myocytes, treatment of atrial natriuretic peptide stimulated the binding of guanosine 3',5'-cyclic monophosphate-dependent protein kinase (PKG) I-alpha to RGS4, PKG-dependent phosphorylation of RGS4, and association of RGS4 and Galpha(q). In contrast, blockade of GC-A by an antagonist, HS-142-1, attenuated the phosphorylation of RGS4 and association of RGS4 and Galpha(q). Moreover, overexpressing a dominant negative form of RGS4 diminished the inhibitory effects of atrial natriuretic peptide on endothelin-1-stimulated inositol 1,4,5-triphosphate production, [(3)H]leucine incorporation, and atrial natriuretic peptide gene expression. Furthermore, expression and phosphorylation of RGS4 were significantly reduced in the hearts of GC-A knockout (GC-A-KO) mice compared with wild-type mice. For further investigation, we constructed cardiomyocyte-specific RGS4 transgenic mice and crossbred them with GC-A-KO mice. The cardiac RGS4 overexpression in GC-A-KO mice significantly reduced the ratio of heart to body weight (P<0.001), cardiomyocyte size (P<0.01), and ventricular calcineurin activity (P<0.05) to 80%, 76%, and 67% of nontransgenic GC-A-KO mice, respectively. It also significantly suppressed the augmented cardiac expression of hypertrophy-related genes in GC-A-KO mice.
CONCLUSIONS: These results provide evidence that GC-A activates cardiac RGS4, which attenuates Galpha(q) and its downstream hypertrophic signaling, and that RGS4 plays important roles in GC-A-mediated inhibition of cardiac hypertrophy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18443239     DOI: 10.1161/CIRCULATIONAHA.107.732990

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  43 in total

Review 1.  Reverse remodeling in heart failure--mechanisms and therapeutic opportunities.

Authors:  Norimichi Koitabashi; David A Kass
Journal:  Nat Rev Cardiol       Date:  2011-12-06       Impact factor: 32.419

Review 2.  A finer tuning of G-protein signaling through regulated control of RGS proteins.

Authors:  Jacob Kach; Nan Sethakorn; Nickolai O Dulin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-04-27       Impact factor: 4.733

3.  Reverse remodelling and recovery from heart failure are associated with complex patterns of gene expression.

Authors:  Leanne Elizabeth Felkin; Enrique A Lara-Pezzi; Jennifer L Hall; Emma J Birks; Paul J R Barton
Journal:  J Cardiovasc Transl Res       Date:  2011-03-22       Impact factor: 4.132

4.  Phosphorylation of TRPC6 channels at Thr69 is required for anti-hypertrophic effects of phosphodiesterase 5 inhibition.

Authors:  Motohiro Nishida; Kenta Watanabe; Yoji Sato; Michio Nakaya; Naoyuki Kitajima; Tomomi Ide; Ryuji Inoue; Hitoshi Kurose
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

5.  Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5.

Authors:  Manling Zhang; Eiki Takimoto; Steven Hsu; Dong I Lee; Takahiro Nagayama; Thomas Danner; Norimichi Koitabashi; Andreas S Barth; Djahida Bedja; Kathleen L Gabrielson; Yibin Wang; David A Kass
Journal:  J Am Coll Cardiol       Date:  2010-10-21       Impact factor: 24.094

Review 6.  Molecular mechanisms underlying cardiac antihypertrophic and antifibrotic effects of natriuretic peptides.

Authors:  Camilla Calvieri; Speranza Rubattu; Massimo Volpe
Journal:  J Mol Med (Berl)       Date:  2011-08-09       Impact factor: 4.599

Review 7.  Involvement of bradykinin in brain edema development after ischemic stroke.

Authors:  Marina Dobrivojević; Katarina Špiranec; Aleksandra Sinđić
Journal:  Pflugers Arch       Date:  2014-04-23       Impact factor: 3.657

8.  Regulation of Gβγi-dependent PLC-β3 activity in smooth muscle: inhibitory phosphorylation of PLC-β3 by PKA and PKG and stimulatory phosphorylation of Gαi-GTPase-activating protein RGS2 by PKG.

Authors:  Ancy D Nalli; Divya P Kumar; Othman Al-Shboul; Sunila Mahavadi; John F Kuemmerle; John R Grider; Karnam S Murthy
Journal:  Cell Biochem Biophys       Date:  2014-11       Impact factor: 2.194

9.  Prevention of PKG-1α Oxidation Suppresses Antihypertrophic/Antifibrotic Effects From PDE5 Inhibition but not sGC Stimulation.

Authors:  Taishi Nakamura; Guangshuo Zhu; Mark J Ranek; Kristen Kokkonen-Simon; Manling Zhang; Grace E Kim; Kenichi Tsujita; David A Kass
Journal:  Circ Heart Fail       Date:  2018-03       Impact factor: 8.790

10.  NO triggers RGS4 degradation to coordinate angiogenesis and cardiomyocyte growth.

Authors:  Irina M Jaba; Zhen W Zhuang; Na Li; Yifeng Jiang; Kathleen A Martin; Albert J Sinusas; Xenophon Papademetris; Michael Simons; William C Sessa; Lawrence H Young; Daniela Tirziu
Journal:  J Clin Invest       Date:  2013-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.